Taksonomicheskiy disbioz mikrobioty i syvorotochnyye biomarkery kak otrazheniye tyazhesti porazheniya tsentral'noy nervnoy sistemy

Aim. To evaluate the safety and efficacy of the adaptive phage therapy technique in patients with recurrent pneumonia in neurological critical care.Material and methods. The clinical study included 83 chronically critically ill patients with severe brain damage. The bacteriophage cocktail selected against specific hospital strains was administered by inhalation to 43 patients. The control group included 40 patients who received conventional antimicrobial therapy. The changes in clinical, laboratory and instrumental parameters, levels of biomarkers, microbiological and PCR tests of bronchoalveolar lavage fluid were assessed, including those in the «phage therapy with antibiotics» (n=29) and «phage therapy without antibiotics» (n=14) subgroups.Results. The groups were comparable in terms of basic parameters (age, sex, diagnosis, organ dysfunction according to APACHE II, use of vasoactive drugs) and the level of airway colonization with antibioticresistant bacterial strains. Good tolerability and absence of clinically significant side effects were observed during inhaled administration of the bacteriophage cocktail. Computed tomography on day 21 showed a significant reduction in lung damage in patients who received bacteriophages. Patients treated with bacteriophages without antibiotics had significantly lower need for mechanical ventilation. The mortality rate on day 28 did not differ significantly and was 4.7% (2/43) in the bacteriophage-treated group vs 5% (2/40) in the control group.Conclusion. The first experience of using the adaptive phage therapy technique in chronically critically ill patients in neurological intensive care demonstrated the safety of inhalational administration of the bacteriophage cocktail. The efficacy of the technique was confirmed by the treatment results obtained in the phage therapy group, which were not inferior to those in the group with conventional antibiotic therapy, while several clinical and laboratory parameters tended to improve even in patients who received bacteriophages and did not receive antibiotics.

show abstract

Adaptive Phage Therapy in the Treatment of Patients with Recurrent Pneumonia (Pilot Study)

Белобородова

Grechko

Gurkova³

et al. 2021

Obŝaâ reanimatologiâ

View full text Add to dashboard Cite

show abstract

Prevention of nosocomial pneumonia recurrence using a bacteriophage cocktail in intensive care unit

Grechko,

Gurkova,

Zhdanova

et al. 2024

Rus. J. Anes. Reanim.

View full text Add to dashboard Cite

Microbiota dysfunction in patients with brain damage in chronic critical condition

Grechko

Buyakova

Белобородова

2022

РНЖ

View full text Add to dashboard Cite

In patients with severe brain damage, the severity of the course/outcome of a chronic critical condition is associated with dysfunction of the intestinal microbiota, which can be assessed by the level of microbial metabolites circulating in the blood.The purpose of the study. To establish a connection between the dynamics of a chronic critical condition developed as a result of severe brain damage and microbiota dysfunction.Patients and methods. The study included 83 patients in chronic critical state (CCS) with the consequences of ischemic/ hemorrhagic stroke (n = 34), traumatic brain injury (n = 18), hypoxic brain damage (n = 7), neurosurgical interventions (n = 7), meningitis (n = 3); and 30 healthy people (control group). To assess the neurological status in dynamics, the stroke scales of the National Institutes of Health (NIHSS), the FOUR, Rankin scales, and the Rivermead Mobility Index were used. The taxonomic composition of the microbiota was evaluated by 16S rRNA sequencing and PCR. Biomarkers (by ELISA Kit) and aromatic microbial metabolites (by GC-MS) were monitored twice a week.Results. The peculiarities of the taxonomic composition of the intestinal microbiota in long-term ill patients with brain damage, the predominance of conditionally pathogenic facultative anaerobes (Klebsiella spp., Proteus spp., Staphylococcus aureus) over the pool of strict anaerobes were revealed. The relationship between the dynamics of microbial metabolites in blood and gut of patients with the course and outcome of the disease has been established. Patients with positive clinical dynamics of CCS were characterized by a stable level or decrease in microbial metabolites during treatment. In the group of patients with negative clinical dynamics, an increase in the level of microbial metabolites, especially hydroxylated phenyl carboxylic acids, was revealed.Conclusion. In patients with brain damage, the levels of microbial metabolites circulating in the blood (p-hydroxyphenylacetic, phenyl-lactic, p-hydroxyphenyl-lactic acids) reflect the degree of microbiota dysfunction and the severity of the course of CCS, which is of prognostic importance.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Taksonomicheskiy disbioz mikrobioty i syvorotochnyye biomarkery kak otrazheniye tyazhesti porazheniya tsentral'noy nervnoy sistemy

Cited by 3 publications

References 0 publications

Adaptive Phage Therapy in the Treatment of Patients with Recurrent Pneumonia (Pilot Study)

Adaptive Phage Therapy in the Treatment of Patients with Recurrent Pneumonia (Pilot Study)

Prevention of nosocomial pneumonia recurrence using a bacteriophage cocktail in intensive care unit

Microbiota dysfunction in patients with brain damage in chronic critical condition

Contact Info

Product

Resources

About